ArticleEuropean journal of medical research2025
Efficacy of ultrasound-guided transabdominal intradetrusor botulinum toxin injection for detrusor overactivity after spinal cord injury.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo compare the efficacy and safety of ultrasound-guided transabdominal versus transurethral cystoscopic botulinum toxin type A (BoNT-A) injection for treating detrusor overactivity (DO) following spinal cord injury (SCI).
methodsIn this retrospective cohort study, we analyzed clinical data from 60 SCI patients with DO treated at Hangzhou Third People's Hospital between January 2020 and June 2025. Patients were divided into two groups: the transabdominal ultrasound-guided group (n = 30) received transabdominal BoNT-A injection (100U, 4-point technique), while the cystoscopic group (n = 30) underwent standard transurethral cystoscopic injection (100U, 20-point technique). Primary outcomes included maximum cystometric capacity (MCC), detrusor pressure at maximum flow rate (Pdet.Qmax), and 24-h urinary incontinence episodes, and key storage-phase safety parameters (detrusor leak point pressure [DLPP] and bladder compliance), assessed at baseline, 1 month, and 6 months post-treatment. Secondary measures comprised the Neurogenic Bladder Symptom Score (NBSS) and Urinary Distress Inventory (UDI-6). Procedure-related complications, visual analog scale (VAS) pain scores (excluding ASIA A patients), and treatment acceptance were recorded within 30 min post-intervention by trained nurses using standardized protocols.
resultsThe 60 enrolled patients showed well-matched baseline characteristics (all P > 0.05). At 1-month follow-up, both groups demonstrated significant improvements in urodynamic parameters (MCC: + 160.87 ± 177.89 mL vs + 157.46 ± 165.53 mL; Pdet.Qmax: -14.70 ± 11.43 cmH₂O vs -14.22 ± 12.17 cmH₂O) and incontinence frequency (-2.72 ± 1.07 vs -2.78 ± 1.15 episodes/day) compared to baseline (all P < 0.05), with no between-group differences in improvement magnitude (all P > 0.05). Critically, storage-phase safety also improved, with significant reductions in DLPP and increases in bladder compliance in both groups (all P < 0.05). The ultrasound-guided group showed superior safety profiles: lower pain scores (3.02 ± 1.27 vs 4.22 ± 1.41, P = 0.003), reduced hematuria (6.67% vs 50.00%, P < 0.001), and fewer urinary tract infections (3.33% vs 20.00%, P = 0.031). Treatment acceptance was significantly higher in the ultrasound-guided group (8.28 ± 1.54 vs 5.86 ± 2.19, P < 0.001). Therapeutic effects remained significantly better than baseline at 6-month follow-up despite partial attenuation (all P < 0.05).
conclusionUltrasound-guided transabdominal BoNT-A injection is as effective as the cystoscopic approach for SCI-induced DO, but offers a superior safety profile and greater patient acceptance. The technique also significantly improves storage-phase safety parameters, making it an advantageous alternative, especially for patients unsuitable for cystoscopy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.